VERTEX PHARMACEUTICALS INC / MA (VRTX) Options Risk Score
Real-time risk analysis for VRTX options traders — updated every 30 minutes.
Data last updated: 2026-09-06
Run a full VRTX options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan VRTX Now — Free →
Is it risky to sell options on VERTEX PHARMACEUTICALS INC / MA (VRTX) right now?
VERTEX PHARMACEUTICALS INC / MA (VRTX) currently scores 19 out of 100 for options catalyst risk (LOW) over a 4-week expiry window. That score is driven by an upcoming earnings report, 2 recent news items, 1 active legal filing and 31 clinical-trial catalysts falling inside the 4-week window. On TickerRisk's scale anything below 45 is LOW, meaning no major scheduled catalyst was found in this window. That is not a guarantee against an unscheduled move — it means the calendar is clear, not that VRTX cannot fall.
VRTX shows an IV Rank of 30, near the low end of its one-year range — options are relatively cheap, which favours option buyers over sellers, with a current implied volatility of about 38%. IV Rank is the most useful figure for deciding whether to sell or buy premium on VRTX.
VRTX is scheduled to report earnings on 2026-11-02, which falls inside a typical monthly options expiry — expect elevated implied volatility into the event and an IV crush afterward.
VERTEX PHARMACEUTICALS INC / MA (VRTX) current implied volatility and IV Rank
VERTEX PHARMACEUTICALS INC / MA (VRTX) currently has an IV Rank of 30 with implied volatility around 38%, alongside a TickerRisk options-risk score of 19/100. That's low — options are cheap relative to the past year, which favours premium-buying strategies such as long calls, long puts and debit spreads when you expect a move.
For what this number does and does not tell you about VRTX's options, see IV Rank explained.
VERTEX PHARMACEUTICALS INC / MA (VRTX) next earnings date — 2026-11-02
VERTEX PHARMACEUTICALS INC / MA (VRTX) is scheduled to report on 2026-11-02 — about 57 days away, so a standard expiry would carry straight through it. VRTX's IV Rank is currently 30. Implied volatility tends to build into the date and drop sharply once results are public. If the premium on VRTX looks unusually generous right now, this is the most likely reason.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer